

Bertrand Cariou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3152324/publications.pdf>

Version: 2024-02-01

149
papers

10,833
citations

44069

48
h-index

32842

100
g-index

153
all docs

153
docs citations

153
times ranked

13675
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1243-1251.e12.	4.4	32
2	History of bariatric surgery and COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. <i>Obesity</i> , 2022, 30, 599-605.	3.0	7
3	Influenza vaccination and prognosis for COVID-19 in hospitalized patients with diabetes: Results from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 343-347.	4.4	2
4	The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 15-27.	4.4	24
5	Seipin localizes at endoplasmic-reticulum-mitochondria contact sites to control mitochondrial calcium import and metabolism in adipocytes. <i>Cell Reports</i> , 2022, 38, 110213.	6.4	29
6	Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. <i>Cardiovascular Diabetology</i> , 2022, 21, 21.	6.8	10
7	COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study. <i>Current Diabetes Reports</i> , 2022, 22, 53-63.	4.2	14
8	Effect of Parathyroidectomy on Metabolic Homeostasis in Primary Hyperparathyroidism. <i>Journal of Clinical Medicine</i> , 2022, 11, 1373.	2.4	3
9	Generation of a GPR146 knockout human induced pluripotent stem cell line (ITXi001-A-1). <i>Stem Cell Research</i> , 2022, 60, 102721.	0.7	6
10	Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102484.	3.6	6
11	APOB CRISPR-Cas9 Engineering in Hypobetalipoproteinemia: A Promising Tool for Functional Studies of Novel Variants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4281.	4.1	6
12	A comment on metformin and COVID-19 with regard to Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1888-1893.	4.4	1
13	Protection by metformin against severe Covid-19: An in-depth mechanistic analysis. <i>Diabetes and Metabolism</i> , 2022, 48, 101359.	2.9	13
14	Impact of diabetes on COVID-19 prognosis beyond comorbidity burden: the CORONADO initiative. <i>Diabetologia</i> , 2022, 65, 1436-1449.	6.3	13
15	Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. <i>Diabetes and Metabolism</i> , 2021, 47, 101202.	2.9	66
16	Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 391-403.	4.4	69
17	Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. <i>Diabetes and Metabolism</i> , 2021, 47, 101216.	2.9	65
18	Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412199592.	2.0	5

#	ARTICLE	IF	CITATIONS
19	Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. <i>Diabetologia</i> , 2021, 64, 778-794.	6.3	120
20	Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1162-1172.	4.4	33
21	Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1069-1083.	4.4	104
22	Diabète et COVID-19: les leçons de CORONADO. <i>Medecine Des Maladies Metaboliques</i> , 2021, 15, 15-23.	0.1	2
23	Impact of parathyroidectomy on cardiovascular risk in primary hyperparathyroidism: A narrative review. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 981-996.	2.6	16
24	La metformine est associée à une moindre mortalité chez les patients diabétiques hospitalisés pour la COVID-19. <i>Medecine Des Maladies Metaboliques</i> , 2021, 15, 278-287.	0.1	0
25	Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108695.	2.8	19
26	Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. <i>Atherosclerosis</i> , 2021, 326, 47-55.	0.8	18
27	Anti-diabetic drugs and NASH: from current options to promising perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 813-825.	4.1	16
28	The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2414-2424.	5.3	44
29	Large-scale screening of lipase acid deficiency in at risk population. <i>Clinica Chimica Acta</i> , 2021, 519, 64-69.	1.1	7
30	Sex disparities in COVID-19 outcomes of inpatients with diabetes: insights from the CORONADO study. <i>European Journal of Endocrinology</i> , 2021, 185, 299-311.	3.7	14
31	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. <i>Diabetes and Metabolism</i> , 2021, 47, 101272.	2.9	18
32	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2632-2640.	2.4	42
33	The association between metformin treatment and COVID-19 outcomes according to metformin continuation during hospitalisation. <i>Diabetes and Metabolism</i> , 2021, 47, 101297.	2.9	7
34	PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. <i>Stem Cell Reports</i> , 2021, 16, 2958-2972.	4.8	7
35	Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e63-e71.	2.4	12
36	Severely uncontrolled diabetes: a new aetiology of acquired bisalbuminaemia. <i>Diabetes and Metabolism</i> , 2020, 46, 341-342.	2.9	0

#	ARTICLE	IF	CITATIONS
37	Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials. <i>Diabetes and Metabolism</i> , 2020, 46, 280-287.	2.9	1
38	Association between sleep disturbances, fear of hypoglycemia and psychological well-being in adults with type 1 diabetes mellitus, data from cross-sectional VARDIA study. <i>Diabetes Research and Clinical Practice</i> , 2020, 160, 107988.	2.8	9
39	Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. <i>Atherosclerosis</i> , 2020, 293, 49-56.	0.8	21
40	EGF-A peptides: A promising strategy for PCSK9 inhibition. <i>Atherosclerosis</i> , 2020, 292, 204-206.	0.8	8
41	Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes. <i>Metabolism: Clinical and Experimental</i> , 2020, 103, 154042.	3.4	21
42	Comment on Chen et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. <i>Diabetes Care</i> 2020;43:1399-1407. <i>Diabetes Care</i> , 2020, 43, e163-e164.	8.6	7
43	SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2020, 306, 41-49.	0.8	30
44	Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2084-2094.	2.4	18
45	PCSK9 post-transcriptional regulation: Role of a 3'UTR microRNA-binding site variant in linkage disequilibrium with c.1420G. <i>Atherosclerosis</i> , 2020, 314, 63-70.	0.8	7
46	Phenotypic Characteristics and Development of a Hospitalization Prediction Risk Score for Outpatients with Diabetes and COVID-19: The DIABCOVID Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3726.	2.4	12
47	Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	54
48	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3613-3682.	3.6	63
49	Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study. <i>Diabetes Care</i> , 2020, 43, e174-e177.	8.6	35
50	Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jani P et al [letter]. <i>Diabetologia</i> , 2020, 63, 2491-2494.	6.3	4
51	A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins. <i>Journal of Lipid Research</i> , 2020, 61, 1128-1139.	4.2	22
52	Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. <i>Diabetologia</i> , 2020, 63, 1500-1515.	6.3	638
53	Improvement in arterial stiffness (pOpm [®]) after bariatric surgery. Results from a prospective study. <i>Annales D'Endocrinologie</i> , 2020, 81, 44-50.	1.4	8
54	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020, 19, 14.	6.8	22

#	ARTICLE	IF	CITATIONS
55	Association of Diabetes and Severe COVID-19 Outcomes: A Rapid Review and Meta-Analysis. <i>Journal of Endocrinology and Metabolism</i> , 2020, 10, 118-130.	0.4	2
56	Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 471-477.	4.4	17
57	Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study. <i>PLoS ONE</i> , 2019, 14, e0221524.	2.5	26
58	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , 2019, 42, 2262-2271.	8.6	146
59	No association between fear of hypoglycemia and blood glucose variability in type 1 diabetes: The cross-sectional VARDIA study. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 554-560.	2.3	8
60	Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 39-51.	4.4	8
61	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , 2019, 42, 919-930.	8.6	51
62	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	8.6	249
63	AB0882 ACROMEGALY DO NOT INCREASE THE RISK OF VERTEBRAL FRACTURES : A RETROSPECTIVE AND PROSPECTIVE STUDY ON 50 PATIENTS. , 2019, , .		0
64	Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature. <i>Endocrine</i> , 2019, 63, 348-360.	2.3	24
65	Predicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing. <i>Journal of the Endocrine Society</i> , 2019, 3, 201-221.	0.2	27
66	Inhibiting PCSK9 biology beyond LDL control. <i>Nature Reviews Endocrinology</i> , 2019, 15, 52-62.	9.6	96
67	Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 420-434.	7.1	31
68	PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1519-1525.	2.6	24
69	Alirocumab vs usual lipid-lowering care as addition to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1479-1489.	4.4	76
70	Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 592-598.	2.4	77
71	Prevalence of hypobetalipoproteinemia and related psychiatric characteristics in a psychiatric population: results from the retrospective HYPOPSY Study. <i>Lipids in Health and Disease</i> , 2018, 17, 249.	3.0	9
72	High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. <i>Atherosclerosis</i> , 2018, 277, 334-340.	0.8	33

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , 2018, 41, 2552-2559.	8.6	177
74	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. <i>Atherosclerosis</i> , 2018, 278, 82-90.	0.8	27
75	HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. <i>Diabetes Care</i> , 2018, 41, 1981-1990.	8.6	138
76	The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. <i>Diabetes</i> , 2017, 66, 1030-1040.	0.6	119
77	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 97-105.	11.4	298
78	Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism. <i>Journal of Clinical Lipidology</i> , 2017, 11, 87-93.	1.5	22
79	34 e CongrÃs SFE Poitiers 2017. <i>Annales D'Endocrinologie</i> , 2017, 78, 199.	1.4	0
80	Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort. <i>Aids</i> , 2017, 31, 2367-2376.	2.2	19
81	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 864-876.	11.4	244
82	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1781-1792.	4.4	105
83	Association Between Hypoglycemia and the Burden of Comorbidities in Hospitalized Vulnerable Older Diabetic Patients: A Cross-Sectional, Population-Based Study. <i>Diabetes Therapy</i> , 2017, 8, 1405-1413.	2.5	16
84	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017, 16, 70.	6.8	25
85	Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 448-451.	4.4	15
86	Post-term growth and cognitive development at 5 years of age in preterm children: Evidence from a prospective population-based cohort. <i>PLoS ONE</i> , 2017, 12, e0174645.	2.5	15
87	E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver. <i>JCI Insight</i> , 2017, 2, .	5.0	39
88	Vitamin D deficiency is an independent risk factor for PTDM after kidney transplantation. <i>Transplant International</i> , 2016, 29, 207-215.	1.6	18
89	Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia. <i>Atherosclerosis</i> , 2016, 250, 52-56.	0.8	17
90	Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. <i>International Journal of Cardiology</i> , 2016, 223, 750-757.	1.7	54

#	ARTICLE	IF	CITATIONS
91	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , 2016, 37, 2981-2989.	2.2	142
92	PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering. <i>Atherosclerosis</i> , 2016, 253, 275-277.	0.8	18
93	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 1501-1509.	8.6	126
94	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β -cell function in the GetGoal-M and GetGoal-S trials. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1385-1392.	2.3	15
95	Role of PCSK9 beyond liver involvement. <i>Current Opinion in Lipidology</i> , 2015, 26, 155-161.	2.7	65
96	Sotagliflozin as a potential treatment for type 2 diabetes mellitus. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1647-1656.	4.1	29
97	Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. <i>DMM Disease Models and Mechanisms</i> , 2015, 9, 81-90.	2.4	34
98	PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. <i>Atherosclerosis</i> , 2015, 239, 252-259.	0.8	35
99	From Human-Induced Pluripotent Stem Cells to Liver Disease Modeling: A Focus on Dyslipidemia. <i>Current Pathobiology Reports</i> , 2015, 3, 47-56.	3.4	2
100	Laparoscopic Gastric Banding in Obese Patients with Sleep Apnea: A 3-Year Controlled Study and Follow-up After 10 Years. <i>Obesity Surgery</i> , 2015, 25, 1886-1892.	2.1	43
101	The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis. <i>Diabetologia</i> , 2015, 58, 2051-2055.	6.3	49
102	Letter From Le May and Cariou Regarding Article, "Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms". <i>Circulation</i> , 2015, 131, e427.	1.6	0
103	mTOR inhibitors and diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 101-108.	2.8	86
104	Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. <i>Clinical Therapeutics</i> , 2015, 37, 1945-1954.e6.	2.5	24
105	Long-term effects of Roux-en-Y gastric bypass on postprandial plasma lipid and bile acids kinetics in female non diabetic subjects: A cross-sectional pilot study. <i>Clinical Nutrition</i> , 2015, 34, 911-917.	5.0	51
106	PCSK9 Inhibition: Does Lipoprotein Size Matter?. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	1
107	PCSK9 inhibition with evolocumab (AMC 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2015, 385, 331-340.	13.7	615
108	GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1441-1448.	4.1	27

#	ARTICLE	IF	CITATIONS
109	The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in <i>db/db</i> mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 440-447.	2.0	31
110	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 121.	1.7	48
111	Function of seipin: New insights from <i>Bscl2/seipin</i> knockout mouse models. <i>Biochimie</i> , 2014, 96, 166-172.	2.6	24
112	Congenital Lipodystrophies and Dyslipidemias. <i>Current Atherosclerosis Reports</i> , 2014, 16, 437.	4.8	20
113	Preserved adrenal function in fully PCSK9-deficient subject. <i>International Journal of Cardiology</i> , 2014, 176, 499-500.	1.7	13
114	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013, 58, 1941-1952.	7.3	355
115	Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. <i>Nutrition and Metabolism</i> , 2013, 10, 4.	3.0	100
116	Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1484-1493.	2.4	150
117	Plasma PCSK9 Is a Late Biomarker of Severity in Patients With Severe Trauma Injury. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E732-E736.	3.6	32
118	Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects. <i>Diabetes Care</i> , 2013, 36, 2923-2930.	8.6	187
119	New avenues for the pharmacological management of type 2 diabetes: An update. <i>Annales D'Endocrinologie</i> , 2012, 73, 459-468.	1.4	5
120	Thiazolidinediones and PPAR γ agonists: time for a reassessment. <i>Trends in Endocrinology and Metabolism</i> , 2012, 23, 205-215.	7.1	342
121	DPP-4 inhibitors in the treatment of type 2 diabetes. <i>Biochemical Pharmacology</i> , 2012, 83, 823-832.	4.4	83
122	TGR5 : un nouveau r�cepteur aux acides biliaires aux propri�t�s m�taboliques. <i>Medecine Des Maladies Metaboliques</i> , 2011, 5, 37.	0.1	1
123	Effects of the New Dual PPAR α/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism. <i>Diabetes Care</i> , 2011, 34, 2008-2014.	8.6	155
124	Clinical aspects of PCSK9. <i>Atherosclerosis</i> , 2011, 216, 258-265.	0.8	135
125	Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. <i>Atherosclerosis</i> , 2011, 219, 342-348.	0.8	35
126	Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. <i>Nutrition and Metabolism</i> , 2011, 8, 48.	3.0	91

#	ARTICLE	IF	CITATIONS
127	Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity. <i>Diabetes</i> , 2011, 60, 1861-1871.	0.6	261
128	Hypertriglycémie et néphropathie chez le diabétique de type 1: acteur ou marqueur ?. <i>Diabetologia Notes De Lecture</i> , 2010, 2, 7-8.	0.0	0
129	Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. <i>Atherosclerosis</i> , 2010, 211, 700-702.	0.8	48
130	High protein intake reduces intrahepatocellular lipid deposition in humans. <i>American Journal of Clinical Nutrition</i> , 2009, 90, 1002-1010.	4.7	120
131	Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 684-690.	2.4	150
132	PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 2191-2197.	2.4	121
133	A corticotroph pituitary adenoma as the initial presentation of familial glucocorticoid deficiency. <i>European Journal of Endocrinology</i> , 2009, 161, 195-199.	3.7	6
134	L'invalidation sélective de la lipase hormonosensible (HSL) dans la cellule bêta pancréatique chez la souris conduit à une hyperglycémie et à un blocage de l'exocytose. <i>Diabetologia Notes De Lecture</i> , 2009, 1, 15-16.	0.0	0
135	Le récepteur CD40 est exprimé dans l'adipocyte chez l'homme: implication dans le dialogue inflammatoire entre lymphocytes et adipocytes. <i>Diabetologia Notes De Lecture</i> , 2009, 1, 27-28.	0.0	0
136	La chirurgie bariatrique améliore la fonction mitochondriale chez les obèses non diabétiques seulement. <i>Diabetologia Notes De Lecture</i> , 2009, 1, 65-66.	0.0	0
137	Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation. <i>Physiological Reviews</i> , 2009, 89, 147-191.	28.8	1,309
138	PCSK9 is expressed in pancreatic Î-cells and does not alter insulin secretion. <i>Biochemical and Biophysical Research Communications</i> , 2009, 390, 1288-1293.	2.1	96
139	Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. <i>FEBS Letters</i> , 2008, 582, 949-955.	2.8	89
140	PCSK9 and LDL cholesterol: unravelling the target to design the bullet. <i>Trends in Biochemical Sciences</i> , 2008, 33, 426-434.	7.5	73
141	Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9. <i>Journal of Biological Chemistry</i> , 2008, 283, 9666-9673.	3.4	80
142	FXR: a promising target for the metabolic syndrome?. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 236-243.	8.7	136
143	FXR deficiency confers increased susceptibility to torpor. <i>FEBS Letters</i> , 2007, 581, 5191-5198.	2.8	30
144	The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. <i>Journal of Biological Chemistry</i> , 2006, 281, 11039-11049.	3.4	463

#	ARTICLE	IF	CITATIONS
145	Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c. <i>Journal of Biological Chemistry</i> , 2006, 281, 6211-6218.	3.4	260
146	The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition. <i>Journal of Biological Chemistry</i> , 2005, 280, 29971-29979.	3.4	186
147	Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. <i>Biochimie</i> , 2005, 87, 93-98.	2.6	32
148	Transient impairment of the adaptive response to fasting in FXR-deficient mice. <i>FEBS Letters</i> , 2005, 579, 4076-4080.	2.8	72
149	Cellular and Molecular Mechanisms of Adipose Tissue Plasticity in Muscle Insulin Receptor Knockout Mice. <i>Endocrinology</i> , 2004, 145, 1926-1932.	2.8	43